The FDA is a government group in the USA. They changed the rules for a new medicine called AMT-130.

FDA 是美國的一個政府機構。他們更改了一款名為 AMT-130 新藥的規定。

Before, the FDA said the medicine did not work. They wanted a new test. Now, the FDA says the old tests are okay. The company uniQure can now ask for approval in 2026.

之前，FDA 表示該藥物無效。他們要求進行一項新測試。現在，FDA 表示舊有的測試是可以接受的。uniQure 公司現在可以在 2026 年申請核准。

Patient groups are very happy. They want the medicine now. But some doctors are careful. They want more tests to be sure the medicine works for a long time.

病人團體非常高興。他們希望現在就能使用該藥物。但部分醫生則持謹慎態度。他們希望進行更多測試，以確保藥物能長期有效。

The FDA changed its mind before on other medicines too. Some people think the FDA is not consistent. After this news, the company's stock price went up a lot.

FDA 之前對其他藥物也曾改變主意。有些人認為 FDA 的標準並不一致。此消息傳出後，該公司的股價大幅上漲。

The FDA gave a way to approve the medicine. But the company still needs more data.

FDA 提供了一種核准該藥物的方法。但公司仍需要更多數據。

The U.S. Food and Drug Administration (FDA) has changed its position on how it will approve AMT-130, an experimental treatment for Huntington's disease developed by uniQure.

美國食品藥品監督局（FDA）改變了對於 uniQure 開發的亨丁頓舞蹈症（Huntington's disease）實驗性治療方案 AMT-130 的審批立場。

This new agreement follows a period of disagreement between the company and the agency. In March, the FDA described the therapy as a failed product because there was not enough data. The agency had previously demanded a new clinical trial using a 'sham surgery' as a control, which many people criticized. However, the FDA has now agreed that a three-year analysis from an earlier stage can be used as the main evidence for a license application. Consequently, uniQure can now seek accelerated approval and plans to submit its application in the third quarter of 2026.

這項新協議是在公司與該機構經歷一段時間的分歧後達成的。三月份，FDA 因為數據不足而將該療法描述為失敗產品。該機構先前要求進行一項使用「偽手術」作為對照組的新臨床試驗，這引起了許多人的批評。然而，FDA 現在同意可以使用早期階段的三年分析作為申請許可的主要證據。因此，uniQure 現在可以尋求加速審批，並計劃在 2026 年第三季提交申請。

There are different views on this decision. The Huntington’s Disease Society of America (HDSA) and other patient groups, who had previously sent petitions to Congress, described the move as a major success. On the other hand, medical experts emphasized that final approval still depends on further studies to prove the treatment works over the long term. Furthermore, the Department of Health and Human Services (HHS) asserted that this approach balances the urgent need for new treatments with the requirement for high scientific standards.

對於這項決定，外界看法不一。美國亨丁頓舞蹈症協會（HDSA）及其他先前向國會遞交請願書的患者團體，將此舉描述為一次重大成功。另一方面，醫學專家強調，最終審批仍取決於進一步的研究，以證明該療法在長期內有效。此外，衛生及公共服務部（HHS） asserted 稱，這種方法在對新療法迫切的需求與對高科學標準的要求之間取得了平衡。

This change is part of a larger trend of inconsistent rules. Similar shifts in requirements have happened with Moderna’s flu vaccine and Sarepta’s Elevidys. These changes have caused concerns about whether the FDA is consistent when overseeing new biotechnologies. Meanwhile, the stock market reacted positively to the news, and uniQure's share price rose by more than 75 percent.

這次變動是規則不一致之大趨勢的一部分。類似的要求轉變也發生在 Moderna 的流感疫苗和 Sarepta 的 Elevidys 上。這些變化引發了人們對 FDA 在監管新生物技術時是否保持一致的擔憂。與此同時，股市對此消息反應正面，uniQure 的股價上漲超過 75%。

The FDA has created a possible path for AMT-130 to be approved, although the final decision depends on future data.

FDA 為 AMT-130 創造了一條可能的獲批路徑，儘管最終決定仍取決於未來的數據。

The U.S. Food and Drug Administration (FDA) has modified its position regarding the approval process for uniQure's experimental Huntington's disease treatment, AMT-130.

美國食品藥品監督管理局 (FDA) 修改了其對於 uniQure 實驗性亨廷頓舞蹈症治療藥物 AMT-130 審批流程的立場。

The current regulatory rapprochement follows a period of institutional friction; in March, the FDA had characterized the therapy as a failed product, with officials citing insufficient data. The agency previously mandated a new clinical trial utilizing a sham surgery control, a requirement that had drawn significant criticism. However, the FDA has now conceded that a three-year analysis from an earlier clinical stage may serve as the primary basis for a Biologics License Application (BLA). This shift enables uniQure to pursue accelerated approval, with a projected application submission in the third quarter of 2026.

目前的監管趨向緩和是經過一段時間的機構摩擦後而來的；在三月時，FDA 曾因數據不足將該療法定性為失敗產品。該機構先前要求必須進行一項採用偽手術對照組的新臨床試驗，而這項要求引起了重大批評。然而，FDA 現在承認，早期臨床階段的三年分析結果可用作生物製劑許可申請 (BLA) 的主要依據。這一轉變使 uniQure 能夠追求加速審批，預計將於 2026 年第三季提交申請。

Stakeholder positioning reveals a dichotomy between clinical caution and patient urgency. The Huntington’s Disease Society of America (HDSA) and other advocacy groups, who previously mobilized via petitions and congressional communications, have characterized the decision as a critical milestone. Conversely, medical experts maintain that approval remains contingent upon the execution of confirmatory studies to validate long-term clinical efficacy. The Department of Health and Human Services (HHS) has asserted that this pathway balances the necessity of addressing unmet medical needs with the maintenance of rigorous scientific standards.

利益相關者的立場顯示出臨床謹慎與患者迫切需求之間的對立。美國亨廷頓舞蹈症協會 (HDSA) 及其他倡議團體先前透過請願和聯絡國會來採取行動，他們將此決定視為一個關鍵里程碑。相反，醫學專家認為，審批仍取決於是否能執行驗證性研究以證實長期臨床療效。美國衛生及公共服務部 (HHS) 則聲稱，此路徑平衡了滿足未盡醫療需求與維持嚴謹科學標準之間的必要性。

This reversal is situated within a broader pattern of regulatory volatility. Similar instances of shifted evidentiary standards have been observed in the processing of Moderna’s mRNA flu vaccine and Sarepta’s Elevidys. Such fluctuations in guidance have prompted concerns regarding the consistency of the FDA's oversight of emerging biotechnologies. Market response to the current development was immediate, with uniQure's share price increasing by over 75 percent.

此次反轉處於一個更廣泛的監管波動模式之中。類似的證據標準變動也曾在 Moderna 的 mRNA 流感疫苗和 Sarepta 的 Elevidys 審批過程中被觀察到。指引的波動引起了對 FDA 監督新興生物技術一致性的擔憂。市場對此次發展反應迅速，uniQure 的股價隨即上漲超過 75%。

The FDA has established a viable regulatory path for AMT-130, though final approval depends on future confirmatory data.

FDA 已為 AMT-130 建立了一條可行的監管路徑，儘管最終審批仍取決於未來的驗證數據。